BSE - Delayed Quote INR

Vista Pharmaceuticals Limited (VISTAPH.BO)

Compare
10.93
-0.57
(-4.96%)
At close: 3:23:46 PM GMT+5:30
Currency in INR All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
99,771
102,878
10,037
3,946
12,664
Cost of Revenue
74,048
91,422
29,647
3,973
7,715
Gross Profit
25,723
11,456
-19,610
-27
4,949
Operating Expense
60,286
50,482
19,214
18,239
29,522
Operating Income
-34,563
-39,026
-38,824
-18,266
-24,573
Net Non Operating Interest Income Expense
-9,132
-10,973
-12,120
-7,341
-14,487
Pretax Income
-43,261
-51,774
-58,763
-26,176
-38,113
Tax Provision
-12,638
-6,654
-2,143
-17,290
-18,026
Net Income Common Stockholders
-30,623
-45,120
-56,620
-8,886
-20,087
Diluted NI Available to Com Stockholders
-30,623
-45,120
-56,620
-8,886
-20,087
Basic EPS
-0.51
-1.03
-1.54
-0.24
-0.54
Diluted EPS
-0.51
-1.03
-1.54
-0.24
-0.54
Basic Average Shares
55,407.31
43,665.81
36,834.62
37,025
37,198.15
Diluted Average Shares
71,794.31
60,052.82
62,829.89
37,025
37,198.15
Rent Expense Supplemental
--
1,080
45
518
486
Total Expenses
134,334
141,904
48,861
22,212
37,237
Net Income from Continuing & Discontinued Operation
-30,623
-45,120
-56,620
-8,886
-20,087
Normalized Income
-30,621.58
-42,882.91
-50,643.21
-8,886
-20,087
Interest Income
--
1,447
1,293
1,657
1,002
Interest Expense
10,526
12,367
13,099
8,976
15,448
Net Interest Income
-9,132
-10,973
-12,120
-7,341
-14,487
EBIT
-32,735
-39,407
-45,664
-17,200
-22,665
EBITDA
-25,395
-32,210
-39,488
-11,038
-15,388
Reconciled Cost of Revenue
74,048
91,422
29,647
3,973
7,715
Reconciled Depreciation
7,340
7,197
6,176
6,162
7,277
Net Income from Continuing Operation Net Minority Interest
-30,623
-45,120
-56,620
-8,886
-20,087
Total Unusual Items Excluding Goodwill
-2
-2,567
-6,203
--
--
Total Unusual Items
-2
-2,567
-6,203
--
--
Normalized EBITDA
-25,393
-29,643
-33,285
-11,038
-15,388
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-0.58
-329.91
-226.21
--
--
3/31/2021 - 12/30/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade